Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03377556
Title Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Talazoparib

Age Groups: adult | child | senior
Covered Countries USA | CAN